Oct 10, 2026 - 7 AI models call the biggest movers after market close. 3 models finished positive

Excluded from performance statistics: the forecast was created after its scoring window began (look-ahead bias). Historical results below are retained for audit only.

Asked Oct 10, 10:45 AM EDT (market closed). Grok 4.5, Muse Spark 1.1, GPT-6, Perplexity, Gemini 1.5 Pro, DeepSeek and Claude Sonnet 5.5 answered the same standard prompt independently. Window: 2026-10-09 to 2026-10-12 (1 trading session). Benchmark: SPY.

Five direction-adjusted close-to-close returns; a down call reverses the sign. The score is the mean signed return, without subtracting the benchmark. In each chart SPY is on the left and the picks on the right, every candle drawn from zero to that asset's move; ✓ marks a pick that moved the way it was called.

Model	Correct	Hit rate	Return	SPY	Directional return
Grok 4.5	2/5	40.00%	-1.30%	-0.06%	-1.30%
Muse Spark 1.1	3/5	60.00%	-1.63%	-0.06%	-1.63%
GPT-6	3/5	60.00%	0.33%	-0.06%	0.33%
Perplexity	3/5	60.00%	0.26%	-0.06%	0.26%
Gemini 1.5 Pro	3/5	60.00%	-0.62%	-0.06%	-0.62%
DeepSeek	2/5	40.00%	-3.63%	-0.06%	-3.63%
Claude Sonnet 5.5	4/5	80.00%	3.13%	-0.06%	3.13%

Grok 4.5

View full picks and reasoning

Friday's session closed higher across major indices amid a mixed sector picture. Wireless tower REITs surged on the SpaceX spectrum acquisition news, which investors viewed as a net positive for infrastructure demand, while the three major US wireless carriers sold off sharply on competition concerns. Biotech and managed-care names advanced on vaccine-related reports and improved Medicare Advantage star ratings. Liquidity was strong in the large-cap names that led the extremes, setting up a weekend digestion of the catalyst before Monday's open.

1. CCI up — confidence 68%. Crown Castle led S&P 500 gainers with a +15.60 percent move on the SpaceX spectrum deal, which is a substantive catalyst because it signals potential incremental tower leasing demand from a new national tenant. Ranking prioritizes the cleanest large-cap infrastructure beneficiary with confirmed volume and market-cap floors. Hypothesis is continuation higher as the deal details continue to be digested; main risk is profit-taking or any clarification that reduces near-term lease upside. Reference price is the regular-session close of 9 October; no fresher quote available on the weekend.
   Return: 1.72%; alpha: 1.78%.
2. MRNA up — confidence 62%. Moderna rose 14.21 percent on reports of an NIH cancer-vaccine push and related trial momentum, a catalyst that is partly substantive (ongoing oncology data) and partly speculative (policy headlines). Ranking reflects the magnitude of the move, ample liquidity, and clear market-cap qualification. Continuation higher is favored on momentum into the next session; risk is that the move was front-loaded and fades without new data. Price used is the 9 October regular close.
   Return: -5.00%; alpha: -4.94%.
3. HUM up — confidence 65%. Humana gained 11.56 percent after CMS improved its Medicare Advantage star ratings, a substantive regulatory catalyst that directly affects bonus payments and margins. Ranking places it after the pure infrastructure and biotech leaders but ahead of the carriers because the catalyst is company-specific and durable. Continuation is expected as the rating impact is quantified; risk is any broader managed-care rotation. Reference price is the 9 October close.
   Return: 0.38%; alpha: 0.44%.
4. TMUS down — confidence 60%. T-Mobile fell 13.27 percent on the same SpaceX spectrum deal that lifted the tower names, reflecting investor concern over satellite competition; the catalyst is substantive in origin but speculative in the magnitude of near-term share-loss assumptions. Ranking reflects the largest absolute carrier decline with full liquidity and size qualification. Continuation lower is the base case while the competitive narrative remains unresolved; risk is a quick rebound if management commentary or further deal details calm fears. Price is the 9 October regular close.
   Return: 2.21%; alpha: -2.15%.
5. T down — confidence 58%. AT&T declined 9.81 percent in sympathy with the other wireless carriers on SpaceX competition headlines, a largely speculative read-through given the company's scale and existing spectrum position. Ranking is last among the five because the move was smaller than TMUS yet still meets every liquidity and size filter. Continuation lower is favored while the sector remains under pressure; risk is mean-reversion given the stock's high dividend and defensive characteristics. Reference price is the 9 October close.
   Return: 1.40%; alpha: -1.34%.

Full prediction and audit record

Muse Spark 1.1

View full picks and reasoning

October 9 was driven by two distinct catalysts: AI optical networking tightness and Medicare Advantage Star Ratings, plus a telecom disruption. LITE and CIEN surged on sold-out optics commentary, FSLY jumped on an Oppenheimer upgrade, HUM jumped on CMS 4-star rating restoration, while T collapsed on SpaceX low-band spectrum purchase. Market is momentum-chasing AI infrastructure but overreacting to competitive headlines in telecom.

1. LITE up — confidence 75%. Lumentum rose 5.22% to $1103.36 on Oct 9 close after CEO said optoelectronic components effectively sold out through early 2029. Catalyst is substantive industry tightness tied to AI data center build. Price used is regular close Oct 9; quote is fresh same day. Market cap $99.95B verified, price $1103.36 meets $5 floor, 20-day dollar volume ~ $6B based on avg 5.49M shares * $1100, well above $20M. Continuation up likely as supply commentary extends momentum.
   Return: -9.78%; alpha: -9.72%.
2. CIEN up — confidence 72%. Ciena rose 5.60% to $449.77 on Oct 9, high $454.73, volume 3.76M vs avg 2.89M. Same AI optical catalyst as LITE, benefiting from bandwidth demand. Market cap $63.78B as of Oct 9 close. Price $449.77 latest close. Average dollar volume ~ $1.3B (2.89M * $449). Substantive demand story supports continuation higher.
   Return: -9.95%; alpha: -9.89%.
3. HUM up — confidence 70%. Humana surged 11.56% to $431.87 on Oct 9 after CMS released 2027 Star Ratings: primary MA contract restored to 4 stars from 3.5, unlocking quality bonus payments for 2028. News described as best since March 2020, with Barclays and Cantor upgrades. Market cap $51.86B as of Oct 9 close. Dollar volume >$500M daily. Catalyst substantive, improves EPS base. Expect continuation up.
   Return: 0.38%; alpha: 0.44%.
4. T up — confidence 65%. AT&T fell 9.81% to $22.18 on Oct 9, down $2.41 on 140M shares. Catalyst: SpaceX agreed Oct 8 to buy Grain Management nationwide 800 MHz spectrum, enabling Starlink Mobile as full carrier, pressuring legacy wireless. Pre-market down 7.2% extending to close down ~10%. Market cap $151.99B. Dollar volume ~ $3.1B (140M * $22). Selloff appears overdone for FCC approval risk and capex reality, so reversal up likely into target session.
   Return: 1.40%; alpha: 1.46%.
5. FSLY down — confidence 60%. Fastly rose 15.86% to $29.30 on Oct 9 on Oppenheimer upgrade to Outperform $35 target citing larger contract values and AI traffic monetization. No company release Oct 8-9, purely analyst-driven speculative catalyst. Market cap $4.67B, price $29.30 close. Average volume 9.14M shares * $29 = ~$265M dollar volume, above threshold. Up move on upgrade without fundamentals likely to fade, so reversal down.
   Return: -9.80%; alpha: 9.86%.

Full prediction and audit record

GPT-6

View full picks and reasoning

Moderately constructive on the broad US equity market but expecting selective mean reversion after the extreme, news-driven moves of October 9. The S&P 500 gained 0.59% on Friday, while individual stocks experienced double-digit movements driven primarily by SpaceX's acquisition of wireless spectrum and Humana's improved Medicare Advantage ratings. The SpaceX transaction represents a substantive competitive development, but its long-term implications are unlikely to be fully realized immediately. Wireless carriers may experience relief buying after exceptionally sharp declines, while tower operators face profit-taking following speculative infrastructure-demand rallies. Humana has a more directly quantifiable fundamental catalyst and could retain some upward momentum. All five selections are established US-listed common stocks with substantial trading liquidity. Latest available quotes are October 9 after-hours prices, approximately 14 hours and 46 minutes old at prediction time. US equity markets are closed on Saturday, October 10. Market capitalizations are reported at the precision published by the source. Exact 20-session average daily dollar-volume figures could not be independently verified. Published 20-day average share volumes and recent price ranges strongly support liquidity above the $20 million threshold, but exact dollar-volume fields are omitted rather than fabricated. Predictions target the October 12 regular-session close relative to the October 9 regular-session close, excluding dividends and trading costs. Ranking reflects estimated directional predictability rather than expected absolute return.

1. TMUS up — confidence 69%. REVERSAL UP. T-Mobile fell 13.27% on October 9, making it one of the day's largest liquid large-cap decliners. The substantive catalyst was SpaceX's approximately $8 billion acquisition of low-band spectrum from Grain Management, creating expectations of greater competition from Starlink Mobile. Reuters confirmed the transaction and the resulting sector-wide selloff. The competitive threat is legitimate, but the spectrum transaction remains subject to regulatory approval, while constructing a comprehensive terrestrial wireless network requires substantial investment and time. A single-session decline exceeding 13% may therefore represent an exaggerated adjustment to a longer-term threat. T-Mobile also maintains substantial existing network infrastructure, an established customer base, and significant recurring revenue. The primary thesis is short-term oversold recovery as investors distinguish future competitive risk from immediate operating results. Risks include fresh negative analyst revisions, sustained institutional selling, and additional announcements from SpaceX that accelerate perceived competitive pressure. The October 9 regular close was $148.58, compared with $171.31 on October 8. The latest verified quote was $148.75 at 7:59 PM EDT on October 9, approximately 14 hours and 46 minutes before prediction time. StockAnalysis reports a market capitalization of $159.38 billion and 20-day average share volume of 5,917,221. These figures strongly support the market-cap and liquidity screens, but an independently verified exact 20-day average daily dollar-volume figure was unavailable. The ranking reflects the combination of exceptional selling intensity, a substantive but long-duration catalyst, and potential relief buying. Source descriptions: StockAnalysis provides price, market capitalization, and volume statistics; Reuters independently documents the SpaceX transaction and wireless-carrier selloff.
   Return: 2.21%; alpha: 2.27%.
2. HUM up — confidence 65%. CONTINUATION UP. Humana advanced 11.56% during the October 9 regular session following a substantive improvement in its 2027 Medicare Advantage Star Ratings. The company reported that 95% of Medicare Advantage members were enrolled in plans rated four stars or higher, supporting expectations for improved quality bonus payments and future profitability. This development is more directly connected to operating economics than speculative sector rotation. Additional analyst upgrades and price-target increases reinforced the positive reassessment. However, the stock opened at $450.49, reached $456.50, and retreated to a $431.87 regular close, demonstrating substantial intraday profit-taking. The forecast anticipates further upward price discovery after the initial announcement, supported by fundamental earnings implications and favorable analyst revisions. Risks include valuation overshoot, renewed selling after the large overnight gap, uncertainty around future reimbursement rates, and investors concluding that the improvement is already fully priced in. The October 9 regular close was $431.87 versus $387.12 on October 8. The latest verified quote was $435.00 at 7:59 PM EDT on October 9, approximately 14 hours and 46 minutes before prediction time. Published market capitalization was $51.86 billion, with 20-day average share volume of 1,423,587. The exact 20-day average daily dollar volume was not independently available; published share-volume and price information indicates liquidity comfortably above the screening threshold. Ranking reflects a company-specific, financially substantive catalyst, balanced against significant intraday rejection of higher prices. Source descriptions: StockAnalysis supplies current quotes and company statistics; Humana's corporate announcement and contemporaneous financial reporting establish the improvement in Medicare ratings.
   Return: 0.38%; alpha: 0.44%.
3. CCI down — confidence 64%. REVERSAL DOWN. Crown Castle surged 15.60% on October 9, placing it among the day's leading large-cap gainers. The rally followed SpaceX's acquisition of low-band wireless spectrum, which investors interpreted as potentially increasing demand for terrestrial cellular infrastructure. The transaction is substantive, but the immediate extrapolation into higher tower leasing revenue is partly speculative. SpaceX's future network architecture, infrastructure spending, partnership decisions, and regulatory timeline remain uncertain. Tower operators may ultimately benefit from additional wireless network investment, but a one-day revaluation of this magnitude could be excessive relative to near-term cash-flow changes. The forecast favors modest profit-taking on October 12 as investors reassess the timing and financial scale of anticipated infrastructure demand. Risks include continued sector-wide momentum, fresh evidence that SpaceX requires substantial tower capacity, and analyst upgrades that validate the higher valuation. Crown Castle closed October 9 at $79.64, compared with $68.89 on October 8. The latest verified after-hours quote was $79.71 at 7:59 PM EDT on October 9, approximately 14 hours and 46 minutes before prediction time. Reported market capitalization was $33.88 billion, with average 20-day share volume of 4,253,301. The exact 20-day average daily dollar-volume figure could not be independently verified, although available liquidity statistics strongly support qualification. Ranking emphasizes the possibility that the market has immediately capitalized a benefit that may take years to materialize. Source descriptions: StockAnalysis provides verified session prices, after-hours quotes, capitalization, and historical volume; Reuters describes the sector-wide infrastructure implications of the SpaceX spectrum deal.
   Return: 1.72%; alpha: -1.66%.
4. AMT down — confidence 62%. REVERSAL DOWN. American Tower gained 9.30% on October 9 as investors reassessed the importance of terrestrial wireless infrastructure following SpaceX's spectrum acquisition. Reuters identified American Tower and other cell-tower operators as beneficiaries of expectations for increased terrestrial network demand. The underlying transaction is substantive, but the immediate anticipated benefit to American Tower's cash flows remains uncertain. SpaceX could pursue alternative infrastructure arrangements or take considerable time to develop its network. Unlike an earnings surprise or a finalized long-term leasing agreement, this catalyst does not presently establish a measurable near-term increase in American Tower's revenue. The forecast expects partial consolidation or profit-taking after Friday's unusually strong sector rally. Risks include continued institutional rotation into tower companies, analyst upgrades, and additional evidence of future infrastructure leasing opportunities. The October 9 regular close was $182.24, a 9.30% gain from the previous regular close. The latest verified after-hours quote was $181.34 at 7:59 PM EDT on October 9, approximately 14 hours and 46 minutes before prediction time. StockAnalysis reports market capitalization of $84.92 billion and 20-day average share volume of 3,154,477. An exact 20-day average daily dollar-volume measurement could not be independently verified; available trading statistics strongly indicate that the stock exceeds the required liquidity threshold. Ranking is lower than Crown Castle because the percentage move was less extreme, potentially limiting the strength of the immediate reversal opportunity. Source descriptions: StockAnalysis provides company trading and valuation statistics; Reuters documents the SpaceX spectrum transaction and the rally in wireless tower operators.
   Return: 0.18%; alpha: -0.12%.
5. ASTS up — confidence 59%. REVERSAL UP. AST SpaceMobile declined 10.48% on October 9 during the broad repricing of satellite and wireless communications businesses following SpaceX's acquisition of low-band spectrum. The substantive event strengthens SpaceX's potential competitive position, but the stock-market response may have insufficiently distinguished AST SpaceMobile's business model from that of conventional wireless operators. AST SpaceMobile seeks to provide direct-to-device satellite connectivity and could potentially remain an attractive infrastructure partner for incumbent carriers facing increased competition from SpaceX. Financial commentary published after the announcement highlighted this possible strategic benefit. Nevertheless, the competing interpretations make the catalyst less straightforward than those affecting the other selections. The forecast expects a partial rebound as investors reassess AST SpaceMobile's potential value to wireless carriers. Risks are unusually high: SpaceX may emerge as a more formidable direct competitor, AST SpaceMobile has significant financing and execution requirements, and elevated short interest could amplify price movements in either direction. The October 9 regular close was $50.97, down from $56.93 on October 8. The latest verified after-hours quote was $50.92 at 7:59 PM EDT on October 9, approximately 14 hours and 46 minutes before prediction time. Published market capitalization was $19.83 billion and average 20-day share volume was 13,419,332. Exact 20-day average daily dollar volume was not independently verifiable, but available trading statistics strongly indicate that the stock exceeds the liquidity requirement. Ranking is fifth because the potential strategic benefit is highly uncertain, and both competitive and financing risks could overwhelm short-term mean reversion. Source descriptions: StockAnalysis confirms the regular-session movement, subsequent quote, capitalization, and trading volume, and aggregates contemporaneous reporting discussing AST SpaceMobile's potential strategic role following the SpaceX announcement.
   Return: 0.97%; alpha: 1.03%.

Full prediction and audit record

Perplexity

View full picks and reasoning

The S&P 500, Dow, and Nasdaq all closed higher on 2026-10-09, but the session produced unusually large, news-driven dispersion in healthcare and telecommunications. Humana and Crown Castle rallied on company- or industry-specific catalysts, while T-Mobile, AT&T, and AST SpaceMobile sold off sharply. For the next session, I favor a partial reversal in the most oversold telecom names, continuation in Humana's fundamental re-rating, and a reversal lower in Crown Castle after its outsized one-day advance.

1. HUM up — confidence 62%. Humana was among the session's leading large-cap gainers, closing up 11.29% at $430.84 on 2026-10-09 after its largest Medicare Advantage contract improved above the bonus-payment threshold, a substantive revenue-relevant catalyst. I expect continuation because the improvement affects future Medicare Advantage bonus revenue rather than being a purely technical momentum move. Risks are profit-taking after the large advance and broader managed-care sector volatility. The reference price is the latest quote found, $436.03 on 2026-10-10; market capitalization was verified at $52.36 billion and average daily share volume at 1.63 million shares, implying ample liquidity.
   Return: 0.38%; alpha: 0.44%.
2. TMUS up — confidence 60%. T-Mobile fell 13.27% on 2026-10-09, closing at $148.58, after SpaceX's announced acquisition of a nationwide 800 MHz spectrum portfolio raised fears of future Starlink-based wireless competition. The catalyst is substantive in its long-run competitive implications, but the immediate revenue impact is uncertain and the transaction remains subject to FCC approval; the extreme one-day de-rating creates scope for a rebound. I expect reversal, with direction up, as investors reassess the near-term earnings impact. Risks include continued sector contagion, additional negative headlines, and the possibility that the market treats the threat as structurally material. The reference price is $148.76 on 2026-10-10; market capitalization was verified at $159.39 billion and average daily share volume at 5.63 million shares.
   Return: 2.21%; alpha: 2.27%.
3. T up — confidence 58%. AT&T declined 10.81% on 2026-10-09 to a $22.18 close, its worst session since 2000, on the same SpaceX spectrum-competition news that hit the wireless group. I expect a reversal higher because the sell-off appears driven by a prospective, FCC-approval-dependent competitive scenario rather than an immediate change to AT&T's current wireless or fiber cash flows. The stock's high dividend yield and valuation may also attract dip buyers. Risks are that investors continue to price a durable competitive threat, that the move was only the first stage of a re-rating, and that telecom-sector sentiment remains weak. The reference price is $22.24 on 2026-10-10; market capitalization was verified at $151.88 billion and average daily share volume at 46.37 million shares.
   Return: 1.40%; alpha: 1.46%.
4. CCI down — confidence 55%. Crown Castle surged 15.73% on 2026-10-09, closing at $79.68, as investors viewed tower operators as relative beneficiaries of SpaceX's push into wireless spectrum and potential network buildout. The catalyst has a substantive industry logic, but the one-day move was exceptionally large and the direct near-term financial benefit to Crown Castle is not yet quantified. I expect reversal, with direction down, as momentum traders take profits and the market distinguishes between a long-duration infrastructure opportunity and immediate earnings accretion. Risks include continued enthusiasm for tower exposure and a broader risk-on session. The reference price is the $79.71 after-hours quote on 2026-10-09; market capitalization was verified at $33.89 billion and average daily share volume at 4.59 million shares.
   Return: 1.72%; alpha: -1.66%.
5. ASTS down — confidence 50%. AST SpaceMobile fell 9.55% during the 2026-10-09 session, with the quoted decline observed at 2:35 PM Eastern; I could not verify a closing percentage from the available sources, so this previous_change_percent reflects the latest verified intraday figure rather than a confirmed regular-session close. The decline occurred alongside the telecom-sector sell-off after SpaceX's spectrum announcement, which may pressure sentiment toward satellite-to-cell competitors. I expect continuation lower because ASTS is a high-beta, pre-profitability name whose valuation is sensitive to competitive and execution narratives. Risks include a sharp rebound if investors view ASTS as a beneficiary of satellite-based connectivity or if the broader telecom selloff stabilizes. The reference price is $50.93 on 2026-10-10; market capitalization was verified at $19.84 billion and average daily share volume at 17.33 million shares.
   Return: 0.97%; alpha: -0.91%.

Full prediction and audit record

Gemini 1.5 Pro

View full picks and reasoning

Equities showed a mixed picture during the source session with major indexes gaining despite high volatility. Telecom towers and managed care names led the gainers on specific company catalysts such as contract upgrades and spectrum agreements, while select tech and healthcare names continued strong rallies. Declines were pronounced in certain wireless telecom operators.

1. CCI up — confidence 75%. Crown Castle shares soared 15.6% following positive sentiment around a reported spectrum agreement involving Grain and SpaceX, as well as a technical breakout that saw active institutional buying. The stock broke heavy resistance. We expect a continuation of the upward move over the next session as momentum funds chase the newly formed higher trading range.
   Return: 1.72%; alpha: 1.78%.
2. HUM up — confidence 70%. Humana rallied 14.82% after the Centers for Medicare and Medicaid Services released 2027 Star Ratings, showing Humana's largest Medicare Advantage contract increased from 3.5 to 4 stars. This critical fundamental catalyst qualifies the company for lucrative quality bonus payments and triggered a massive short squeeze. We anticipate a continuation of the uptrend.
   Return: 0.38%; alpha: 0.44%.
3. MRNA up — confidence 65%. Moderna shares added 14.2% during the session, extending a powerful one-month surge of roughly 65%. While technically overbought, momentum remains robust and short sellers are being forced to cover. We predict a brief continuation of the rally in the next trading session before any significant pullback materializes.
   Return: -5.00%; alpha: -4.94%.
4. TMUS down — confidence 60%. T-Mobile US plunged 13.27%, tracking for its lowest close since late 2023. This severe negative momentum suggests institutional distribution and broader sector rotation away from the name. We anticipate the downward pressure will continue into the next session as analysts revise price targets lower.
   Return: 2.21%; alpha: -2.15%.
5. DDOG down — confidence 60%. Datadog cleared a major technical resistance level to reach a new 52-week high, rising 7.1%. Despite some insider selling over the past 90 days, the breakout attracts fresh momentum buyers. However, given the sharp intraday move and high valuation multiples, we hypothesize a minor mean-reversion reversal for the upcoming target session as traders lock in quick gains.
   Return: -2.04%; alpha: 2.10%.

Full prediction and audit record

DeepSeek

View full picks and reasoning

The October 9, 2026 session was defined by a single dominant catalyst: SpaceX's $8 billion purchase of nationwide low-band spectrum from Grain Management, which crushed wireless carriers (TMUS -13.27%, T -9.81%, VZ -8.75%) while boosting cell tower operators (CCI +15.60%) on expectations of increased infrastructure demand. A separate regulatory catalyst moved healthcare names in opposite directions: Humana (HUM +11.56%) rallied on improved 2027 Medicare Advantage star ratings, while Alignment Healthcare (ALHC -13.38%) sank after its flagship California HMO contract was downgraded from 4.0 to 3.5 stars. Biotechnology stocks also surged on a new NIH personalized cancer vaccine initiative (MRNA +14.21%, NVAX +15.80%), with Fastly (FSLY +15.86%) jumping on an Oppenheimer upgrade. The market appears to be in a stock-picking regime where sector-specific regulatory and competitive developments overwhelm broad index moves. Into the October 12 target session, I expect the telecom sector to remain under pressure as the market digests SpaceX's long-term competitive threat, healthcare winners and losers to separate further on the CMS rating divergence, and the speculative vaccine rally to face profit-taking given elevated short interest and lack of fundamental earnings follow-through.

1. FSLY up — confidence 72%. Fastly surged 15.86% on October 9 after Oppenheimer upgraded the stock to Outperform from Perform with a $35 price target, citing strong industry checks showing growing contract values, rising adoption of newer security products, and early monetization of agentic AI traffic. The analyst's price target implies roughly 19% upside from the $29.30 close, and the upgrade is backed by substantive industry-level evidence rather than speculation. FSLY gapped up and closed near its daily high of $30.19 on volume of 15.2 million shares, well above its 20-day average of 8.2 million. Reference price is the October 9, 2026 regular-session close of $29.30. Market cap and dollar volume were confirmed against stockanalysis.com and Mitrade data. The primary risk is that a single analyst upgrade can be faded, especially after a 16% single-day move.
   Return: -9.80%; alpha: -9.73%.
2. NVAX down — confidence 65%. Novavax rallied 15.80% on October 9 as part of a broad vaccine-sector surge tied to an NIH personalized cancer vaccine initiative and residual speculative buying from unconfirmed plague reports out of Siberia. The stock carries a short float above 33%, making the move partially a short squeeze rather than a fundamental re-rating. Unlike Moderna, Novavax has no clear revenue catalyst from the cancer vaccine initiative, and its rally appears driven more by sentiment than by a substantive change in its business outlook. The stock closed at $12.75 on volume of 19 million shares versus a 20-day average of 7.9 million. Reference price is the October 9 regular-session close. Market cap and dollar volume were confirmed against stockanalysis.com and Mitrade. The main risk to the reversal thesis is that sector momentum and short covering could extend the rally.
   Return: -0.71%; alpha: 0.77%.
3. TMUS down — confidence 74%. T-Mobile plunged 13.27% on October 9 after SpaceX announced an approximately $8 billion cash purchase of nationwide low-band spectrum from Grain Management, signaling Elon Musk's intent to turn Starlink into a major US mobile carrier. The catalyst is substantive: this represents a structural competitive threat to incumbent wireless carriers with a well-capitalized new entrant. TMUS closed at $148.58, near its daily low of $147.90, on volume of 19 million shares versus a 20-day average of 5.9 million, indicating heavy institutional selling. Reference price is the October 9 regular-session close. Market cap and dollar volume were confirmed against stockanalysis.com and Mitrade. The primary risk to the continuation thesis is that the sell-off may have been overdone on day one and a relief bounce is possible.
   Return: 2.21%; alpha: -2.15%.
4. HUM up — confidence 70%. Humana surged 11.56% on October 9 after CMS released 2027 Medicare Advantage star ratings showing that 95% of its members are enrolled in plans rated at least four stars, a substantial improvement that bodes well for future revenue and margin expansion. Baird upgraded the stock to Buy on the improved ratings. The catalyst is substantive and regulatory in nature, with direct implications for bonus payments and plan competitiveness. HUM closed at $431.87 on volume of 5 million shares versus a 20-day average of 1.4 million. Reference price is the October 9 regular-session close. Market cap and dollar volume were confirmed against stockanalysis.com and Mitrade. The main risk is that the stock gapped up significantly and may see profit-taking after a large one-day move.
   Return: 0.38%; alpha: 0.44%.
5. ALHC down — confidence 68%. Alignment Healthcare sank 13.38% on October 9 after CMS downgraded its California HMO contract (H3815) from 4.0 to 3.5 stars for 2027, affecting approximately 75% of its health plan members. William Blair downgraded the stock to Market Perform from Outperform, and JPMorgan cut its price target to $10 from $22, though it maintained an Overweight rating. The catalyst is substantive and regulatory, with direct negative implications for revenue and margins. ALHC closed at $7.55, near its daily low of $6.01, on volume of 26 million shares versus a 20-day average of 14.3 million. Reference price is the October 9 regular-session close. Market cap and dollar volume were confirmed against stockanalysis.com and Mitrade. The main risk to the continuation thesis is that the stock has already fallen 35% over the past month and may be approaching a valuation floor.
   Return: 7.22%; alpha: -7.16%.

Full prediction and audit record

Claude Sonnet 5.5

View full picks and reasoning

The S&P 500 rose about 0.6% on Friday October 9 to 7,811.5, near its record high. Friday's biggest large-cap moves came from two catalysts: SpaceX's roughly $8B low-band spectrum purchase, which crushed wireless carriers and lifted tower REITs, and 2027 Medicare Advantage Star Ratings, which helped Humana. Next week brings CPI on Wednesday and bank earnings starting Tuesday. Monday October 12 is a US market session, though the bond market is closed. I treat the speculative, narrative-driven moves (the carrier sell-off, the tower rally, Moderna's index-inclusion run, Fastly's upgrade pop) as reversal candidates. I treat the move with a quantifiable earnings effect (Humana's ratings and bonus payments) as a continuation candidate. All five picks pass the price, market-cap and dollar-volume screens with wide margins. Prices are the Friday October 9 regular-session close, the latest regular-session price available on Saturday October 10, plus after-hours quotes where noted. Average 20-day dollar volume is estimated as the 20-day average share volume times the October 9 close, not an exact average of daily dollar volumes. Treat all of this as a low-confidence directional bet, since single-day outcomes are close to coin flips.

1. HUM up — confidence 58%. Humana rose 11.56% on October 9 to a $431.87 close, a 52-week high, after the 2027 Medicare Advantage Star Ratings restored 4 stars to its largest contract (H5216, over 2 million members). The company says 95% of its Medicare Advantage members are now in plans rated 4 stars or higher, which supports quality bonus payments. The catalyst is substantive and quantifiable. Barclays raised its target to $582 and Baird upgraded with a $596 target, both above the price, though the consensus target of about $453 is only about 5% higher. The stock traded at $435.00 after hours (+0.72%), a mildly positive sign. I expect post-ratings drift as analysts revise 2027 and 2028 estimates, so I picked continuation with direction up. Risks: this is a crowded one-day re-rating, so some profit-taking is plausible, and I could not confirm the exact 20-day average dollar volume. The figure is 20-day average shares (1,423,587) times the October 9 close. Price source: October 9 close, 1 day stale, market closed for the weekend.
   Return: 0.38%; alpha: 0.44%.
2. MRNA down — confidence 57%. Moderna rose 14.21% on October 9 to a $225.00 close, a new 52-week high, on its Nasdaq-100 inclusion (effective that day, replacing Warner Bros. Discovery). The catalyst is largely technical and speculative: index funds had to buy by the close, and that demand is now spent. The stock is up about 65% in a month and about 700% in a year. RSI is 72, the consensus target of $122.67 is about 45% below the price, and Citi downgraded it to Sell on September 30 for valuation. Net losses are about $3.15B over the last twelve months. Short interest is about 8% of shares outstanding, so a squeeze could continue the run. Given the stretched valuation and the end of forced buying, I picked reversal with direction down. Risks: strong momentum, a heavily shorted name, and possible further cancer-vaccine news flow around the ESMO congress. After-hours was $225.45 (+0.20%). The 20-day average dollar volume is estimated as 17,628,525 shares times the October 9 close rather than an exact figure. Price source: October 9 close, 1 day stale.
   Return: -5.00%; alpha: 5.06%.
3. TMUS up — confidence 55%. T-Mobile fell 13.27% on October 9 to a $148.58 close, a 52-week low, after SpaceX agreed to buy about $8B of low-band spectrum from Grain Management for a satellite-plus-terrestrial mobile network. The threat is real but long-dated and speculative: the deal still needs FCC approval, and SpaceX has a long way to go to challenge the three big carriers. The sell-off was also broad (AT&T -9.8%, Verizon -8.7%), which suggests sector-wide overshoot. RSI is 29, the price is about 15% below the 50-day average ($174.85), and fundamentals are unchanged. The company has a 3.15% dividend yield, a 4.5% net buyback yield and a consensus target of $241.71. It reports earnings on October 28. I picked reversal with direction up, a bounce from an oversold level. The stock was $148.75 after hours (+0.11%). Risks: further SpaceX or FCC headlines, and momentum selling after a three-year low. The 20-day average dollar volume is estimated as 5,917,221 shares times the October 9 close, not an exact figure. Price source: October 9 close, 1 day stale.
   Return: 2.21%; alpha: 2.27%.
4. CCI down — confidence 52%. Crown Castle rose 15.60% on October 9 to a $79.64 close, the best performer in the S&P 500 that day. The catalyst is largely speculative: SpaceX buying nationwide low-band spectrum is read as a new potential tenant for tower leases, but no lease has been announced and the network is not built. The stock is up about 20% in five days, RSI is 71.75, and the price is above its 50-day average ($73.36). Its earnings report is not until October 21. I picked reversal with direction down, a partial giveback of the one-day jump. Risks: the tower sector (American Tower, SBA) could keep rallying on analyst notes, the dividend yield near 5% attracts buyers, and the consensus target of $94.45 is well above the price. The stock was $79.71 after hours (+0.09%). The 20-day average dollar volume is estimated as 4,253,301 shares times the October 9 close, not an exact figure. Price source: October 9 close, 1 day stale.
   Return: 1.72%; alpha: -1.66%.
5. FSLY down — confidence 48%. Fastly rose 15.86% on October 9 to a $29.30 close after Oppenheimer upgraded it to Outperform with a $35 target, citing contract-value growth, security attach rates and early agentic-AI traffic monetization. The catalyst is an analyst opinion rather than new company results, so I classify it as speculative. The stock is up about 240% in 52 weeks and sits above the consensus target of $28.55. It is also well above its 50-day average ($24.85) and, with a 52-week high of $34.82, is near the top of its range after a series of sharp rallies. Its next earnings report is November 4. I picked reversal with direction down. This is the lowest-conviction pick because short interest is about 13.5% of shares outstanding, so a squeeze could extend the gain. After hours it traded at $29.40 (+0.34%). The 20-day average dollar volume is estimated as 8,198,155 shares times the October 9 close, not an exact figure. Price source: October 9 close, 1 day stale.
   Return: -9.80%; alpha: 9.86%.

Full prediction and audit record

How models have done in Extreme Movers

ForecastNest's own settled Extreme Movers runs at this horizon, up to and including this one. Members' own research is not counted. Runs created after their scoring window began, or with an unverified start time, are excluded. The chart is the average directional return per run. A bar drawn pale is inside its own sample noise -- the runs behind it scatter too widely for that average to separate from zero -- so read the ordering as provisional until the record is deep enough to carry it. The table below adds how many of the five directions were called correctly, which is a steadier measure on a short record because it counts several picks a run rather than one result.

Chart note — “within noise”: The pale bar means the observed average is not clearly separated from zero by this chart's rule, or there is not enough information to assess it. A solid bar requires an average at least two standard errors from zero (standard error = sample standard deviation ÷ √runs). Fewer than two runs, missing variability, or zero measured variability remain pale. This is a rough uncertainty indicator, not proof of no effect or a guarantee of future performance.

Model	Runs	Avg directions called correctly	Avg directional return
DeepSeek	18	48.89%	+0.88%
Claude Sonnet 5.5	8	55.00%	+0.82%
Grok 4	2	50.00%	+0.31%
Gemini 3 Pro	2	60.00%	+0.31%
Grok 4.5	13	43.08%	+0.04%
Claude Opus 5	6	60.00%	+0.03%
Claude Opus 5.5	3	33.33%	-0.24%
Muse Spark 1.1	16	38.75%	-0.32%
Perplexity	11	40.00%	-0.45%
Gemini 1.5 Pro	15	48.00%	-0.65%
GPT-6	6	40.00%	-2.12%
GPT-5.6 Sol	10	46.00%	-3.06%

View settlement prices

Symbol	Start	End	Source	Notes
ALHC	7.54500000	8.09000000	https://finance.yahoo.com/quote/ALHC/history/
AMT	182.24000000	182.56000000	https://finance.yahoo.com/quote/AMT/history/
ASTS	50.96500000	51.46000000	https://finance.yahoo.com/quote/ASTS/history/
CCI	79.64000000	81.01000000	https://finance.yahoo.com/quote/CCI/history/
CIEN	449.77000000	405.01000000	https://finance.yahoo.com/quote/CIEN/history/
DDOG	293.26000000	287.29000000	https://finance.yahoo.com/quote/DDOG/history/
FSLY	29.30000000	26.43000000	https://finance.yahoo.com/quote/FSLY/history/
HUM	431.87000000	433.50000000	https://finance.yahoo.com/quote/HUM/history/
LITE	1103.35500000	995.41000000	https://finance.yahoo.com/quote/LITE/history/
MRNA	225.00000000	213.74000000	https://finance.yahoo.com/quote/MRNA/history/
NVAX	12.75000000	12.66000000	https://finance.yahoo.com/quote/NVAX/history/
SPY	778.57000000	778.10000000	https://finance.yahoo.com/quote/SPY/history/
T	22.18000000	22.49000000	https://finance.yahoo.com/quote/T/history/
TMUS	148.58000000	151.87000000	https://finance.yahoo.com/quote/TMUS/history/

Standard prompt extreme-movers-v11, SHA-256 e21ad0826557909d090d70dcb8bca0834f7abb75f122008c2cac86a654973480. The prompt is available to ForecastNest members; the fingerprint shows it was not changed after the fact.

Calculation: extreme-movers-v1.